Skip to content

Safety of Sticker Pad Containing Essential Oil Containing Lavender and Ylang-ylang Oil

Safety of Sticker Pad Containing Essential Oil Containing Lavender and Ylang-ylang Oil Attached to the Collar for Decrease Blood Pressure in Healthy Volunteer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05791266
Enrollment
56
Registered
2023-03-30
Start date
2022-03-21
Completion date
2023-02-20
Last updated
2023-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The aims of the study were to evaluate safety of sticker pads containing lavender and ylang ylang oil in healthy volunteers.

Detailed description

The lavender and ylang ylang oil pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad. Adverse reactions, irritation score, and quality of life were assessed. Blood pressure and pulse rate were also measured

Interventions

Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* age 18 to 60 years * no allergic history of lavender and ylang ylang oil * no dermatological diseases, immunocompromised diseases, seizures, asthma, or respiratory diseases.

Exclusion criteria

* an unstable condition of other diseases * olfactory problems * pregnancy * lactation

Design outcomes

Primary

MeasureTime frameDescription
Adverse reactions of the respiratory tract, skin, eye, and central nervous system2 hoursThe severity scores were 0 (no symptoms) to 3 (severe symptoms)

Secondary

MeasureTime frameDescription
Irritation of eye, respiratory, other neurological, and toxicity reaction2 hoursUsing a 0 to 100 scale, following an increase of severity
Systolic blood pressure2 hoursMeasure systemic blood pressure in mmHg
Diastolic blood pressure2 hoursMeasure diastolic blood pressure in mmHg
Pulse rate2 hoursMeasure pulse rate in beats/minutes
Rhinoconjunctivitis quality of life questionnaire2 hoursUsing a score of 1 (no problems) to 5 (severe problem)

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026